GSK's (GSK) Hold Rating Reiterated at Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank reaffirmed its Hold rating on GSK with a GBX 2,000 price target, implying 4.33% upside from the prior close.
• Analyst sentiment is mixed but averages to Hold: three Buy, four Hold, and one Sell rating, with a consensus target of GBX 2,145.
• GSK shares rose 0.7% to GBX 1,917 on Tuesday. The company reported quarterly EPS of GBX 54.60 and revenue of GBX 888.70 billion.

GSK (LON:GSK - Get Free Report)'s stock had its "hold" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft in a note issued to investors on Tuesday, Digital Look reports. They currently have a GBX 2,000 price objective on the stock. Deutsche Bank Aktiengesellschaft's price objective would suggest a potential upside of 4.33% from the company's previous close.

Several other research firms have also recently issued reports on GSK. Berenberg Bank reissued a "buy" rating and issued a GBX 2,200 target price on shares of GSK in a research report on Tuesday, November 3rd. Jefferies Financial Group reaffirmed a "buy" rating and set a GBX 2,500 price target on shares of GSK in a research report on Tuesday, October 20th. Finally, Royal Bank Of Canada initiated coverage on shares of GSK in a research note on Tuesday, September 8th. They set a "sector perform" rating and a GBX 1,975 price target on the stock. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of GBX 2,145.

GSK Trading Up 0.7%

GSK stock traded up GBX 12.50 during trading on Tuesday, hitting GBX 1,917. The company's stock had a trading volume of 4,785,284 shares, compared to its average volume of 12,145,941. The stock's fifty day moving average is GBX 1,843.25 and its 200 day moving average is GBX 1,950.04. GSK has a 1-year low of GBX 1,690 and a 1-year high of GBX 2,282. The stock has a market capitalization of £76.85 billion, a price-to-earnings ratio of 17.93, a P/E/G ratio of 1.24 and a beta of 0.28. The company has a debt-to-equity ratio of 126.38, a quick ratio of 0.73 and a current ratio of 0.86.

GSK (LON:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The company reported GBX 54.60 EPS for the quarter. GSK had a return on equity of 24.64% and a net margin of 12.97%. The company had revenue of GBX 888.70 billion during the quarter. As a group, equities research analysts predict that GSK will post 175.98 EPS for the current year.

Insiders Place Their Bets

In other GSK news, insider Jonathan Symonds bought 1,500 shares of GSK stock in a transaction that occurred on Friday, September 18th. The shares were acquired at an average price of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal purchased 637 shares of the firm's stock in a transaction that occurred on Friday, September 18th. The shares were acquired at an average cost of GBX 4,985 per share, with a total value of £31,754.45. In the last three months, insiders bought 2,151 shares of company stock worth $6,021,921. Insiders own 0.20% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.